Developing Story
Indian Pharma Distribution – NDPS/BNS Enforcement vs. Licensing Conflict
Indian pharmaceutical stockists operating under valid Drug & Cosmetics Act licenses are facing NDPS Act and BNS criminal prosecutions for dealing in scheduled cough syrups — creating a dangerous compliance trap. The conflict between regulatory authorization and criminal enforcement has no clear judicial resolution and poses structural legal risk for pharma distribution businesses.
Importance: 68%Confidence: 82%Mentions: 1Updated: April 12, 2026
## Indian Pharma Distribution – NDPS/BNS Enforcement vs. Licensing Conflict
### Overview
A systemic conflict has emerged in India between licensed pharmaceutical stockists operating under the Drugs and Cosmetics Act and law enforcement agencies invoking the Narcotic Drugs and Psychotropic Substances (NDPS) Act and Bharatiya Nyaya Sanhita (BNS) against them for dealing in scheduled cough syrups and similar products. The trend is creating criminal liability exposure for businesses operating entirely within regulatory frameworks.
### The Core Conflict
- **Regulatory framework**: Under the Drugs and Cosmetics Act, licensed wholesalers and stockists are legally authorized to distribute Schedule H, H1, and certain controlled formulations including codeine-based cough syrups.
- **Enforcement action**: Police and narcotics agencies are invoking NDPS Act provisions and BNS sections against the same stockists, treating licensed pharmaceutical inventory as contraband.
- **Jan Vishwas Act tension**: The government's Jan Vishwas (Amendment of Provisions) Act, 2023 sought to decriminalize minor regulatory violations — yet enforcement on the ground is moving in the opposite direction.
### Legal Dimensions
- **Dual regulatory exposure**: Businesses face the risk that compliance with drug licensing rules does not insulate against criminal prosecution under NDPS — creating a compliance trap.
- **NDPS Act severity**: NDPS offenses carry mandatory minimum sentences and are non-bailable in many circumstances, making wrongful prosecution devastating to businesses.
- **Judicial inconsistency**: Courts have in some cases upheld NDPS prosecutions of licensed stockists; in others, granted relief based on Drugs Act licensing. No clear Supreme Court precedent resolves the conflict.
- **Rule of law concern**: The blurring of regulatory violation and criminal conduct undermines predictability for domestic and foreign pharmaceutical distributors.
### Business Implications
- Pharmaceutical distributors and wholesalers in India face structurally elevated legal risk even with full licensing compliance.
- Supply chain participants (manufacturers, CFA agents, retail pharmacies) should audit their exposure to NDPS enforcement risk on scheduled products.
- Foreign pharma companies with Indian distribution operations should assess whether their Indian partners are exposed.
### Watch Points
- Any Supreme Court or High Court ruling clarifying the NDPS vs. Drugs Act boundary for licensed stockists
- Parliamentary action to amend NDPS or clarify Jan Vishwas Act scope
- Industry association (AIOCD, IDMA) lobbying and litigation strategy
- Whether enforcement pattern spreads to other scheduled drug categories beyond cough syrups